CSPC Pharmaceutical Group (01093.HK) reported H1 2026 revenue of RMB 18.594 billion (+40.1% y/y) and net profit attributable to shareholders of RMB 6.094 billion (+139.2% y/y); core profit was RMB 6.164 billion (+165.8% y/y); basic EPS was RMB 0.5345.
Jin1008/20, 11:21 AM
- 40.1%
- 139.2%
- 165.8%
- 139.8%
Figures as quoted by Jin10
Related assets
Coming up for 01093.HK
Explore next
Latest 01093.HK news
Jin1008/13, 09:41 AM
Jin1007/30, 08:19 AM
Jin1007/25, 11:23 PM